NephroGenex (NRX) Tops Q3 EPS by 12c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
- Exclusive-Silver Lake in talks to buy Workday, sources say
- Crude Inventory Rose 17.2 Million Barrels Last Week - EIA
- Citi agrees to acquire rewards platform Kard Financial
- Total darkness, then sunset as full eclipse wows spectators in Spain
- Burry doubles down on Nebius short after stock surges 34% on earnings
NephroGenex Reports Third Quarter 2015 Financial Results
November 11, 2015 4:05 PM ESTConference call and webcast to be held Thursday, November 12, 2015 at 8:30 a.m. EST
RALEIGH, N.C.--(BUSINESS WIRE)-- NephroGenex, Inc. (Nasdaq: NRX), a pharmaceutical company focused on the development of therapeutics to treat kidney disease, today reported financial results and business highlights for the third quarter ended September 30, 2015.
During the third quarter of 2015, we continued to make progress in advancing our Phase 3 study of oral Pyridorin for the treatment of diabetic nephropathy, adding new clinical sites and increasing the number of randomized patients. We remain on track to complete... More
